Alexandr Gish
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alexandr Gish has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Michel Gaulier
CHU Lille, Unité Fonctionnelle de Toxicologie, Lille, France
5 shared publications - Delphine Allorge
Service de Toxicologie et Génopathies, CHU Lille, Lille, France
4 shared publications - Florian Hakim
CHU Lille, Unité Fonctionnelle de Toxicologie, Lille, France
4 shared publications - Camille Richeval
CHU Lille, Unité Fonctionnelle de Toxicologie, Lille, France
3 shared publications Agnès Letrillart
Centre antipoison et de Toxicovigilance de Lille , CHU de Lille, 59000 Lille Cedex, France
1 shared publication- Chadi Abbara
Service de Pharmacologie-Toxicologie Et Pharmacovigilance, Centre Hospitalo-Universitaire D’Angers, Angers, France
1 shared publication
Latest Publications
- 9 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Endocannabinoïdes et cannabinoïdes : biomarqueurs, matrices alternatives, méthodes alternatives de prélèvement et applications en toxicologie biologique et médicolégale
Les cannabinoïdes, au sens large de ce terme (endocannabinoïdes, cannabis, cannabidiol, cannabinoïdes de synthèse ou d’hémisynthèse), font partie des sujets d’actualité pour des raisons scientifiques, sociétales et médiatiques. Cependant, et malgré de nombreuses recherches dans le domaine médical, plusieurs aspects pharmacologiques et toxicologiques de ces substances demeurent mal connus. La complexité de recherche analytique des molécules agissant sur les récepteurs cannabinoïdes réside d’une part, dans la multitude et la variété des cannabinoïdes endogènes (endocannabinoïdes) et exogènes (phytocannabinoïdes, cannabinoïdes de synthèse et d’hémisynthèse), et d’autre part dans leurs particularités physicochimiques, des concentrations circulantes généralement très faibles dans les matrices biologiques et un métabolisme parfois intense. Compte tenu de ces difficultés, la capacité d’identifier et de quantifier ces molécules présente de nombreux écueils sur les plans pré-analytique, analytique et post-analytique. L’objectif de ma thèse était d’appréhender ces difficultés et d’étudier les implications des endocannabinoïdes, et des cannabinoïdes en général, dans les domaines de la toxicologie biologique et médico-légale à travers le développement d’outils analytiques permettant leurs mises en évidence dans les différentes matrices biologiques.A cet effet, trois méthodes analytiques de quantification d’endocannabinoïdes et de substances endocannabinoïdes-like dans trois matrices biologiques différentes (plasma, cheveux et spot de sang séché - DBS), ainsi qu’un outil d’exploration de métabolisme in silico des cannabinoïdes de synthèse, ont été développées. Ces outils ont été mis en oeuvre dans 3 projets de recherche et ont permis (i) d’étudier la relation entre cannabinoïdes sériques et insulinorésistance chez des personnes coinfectées VIH-VHC et d’explorer les effets (de la guérison VHC et de la prise de cannabinoïdes) sur les endocannabinoïdes, (ii) d’étudier l’évolution des endocannabinoïdes dans le sang en période post-mortem, et (iii) d’étudier le métabolisme de 13 « nouveaux » cannabinoïdes de synthèse, pour certains, non décrit précédemment dans la littérature, circulant en 2023 sur l’île de Mayotte, France.Au total, ce travail réalisé au cours de ces trois années de thèse m’a permis d’élaborer des outils analytiques de détection et quantification d’endocannabinoïdes et de cannabinoïdes exogènes dans différentes matrices (et avec des méthodes alternatives de prélèvement sanguin) ; outils complétés de procédures in silico de prédiction à la fois du métabolisme et des paramètres analytiques de biomarqueurs (métabolites) d’exposition qui pourront être appliquées à un périmètre élargi en toxicologie biologique et médicolégale.
- 9 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Endocannabinoïdes et cannabinoïdes : biomarqueurs, matrices alternatives, méthodes alternatives de prélèvement et applications en toxicologie biologique et médicolégale
Les cannabinoïdes, au sens large de ce terme (endocannabinoïdes, cannabis, cannabidiol, cannabinoïdes de synthèse ou d’hémisynthèse), font partie des sujets d’actualité pour des raisons scientifiques, sociétales et médiatiques. Cependant, et malgré de nombreuses recherches dans le domaine médical, plusieurs aspects pharmacologiques et toxicologiques de ces substances demeurent mal connus. La complexité de recherche analytique des molécules agissant sur les récepteurs cannabinoïdes réside d’une part, dans la multitude et la variété des cannabinoïdes endogènes (endocannabinoïdes) et exogènes (phytocannabinoïdes, cannabinoïdes de synthèse et d’hémisynthèse), et d’autre part dans leurs particularités physicochimiques, des concentrations circulantes généralement très faibles dans les matrices biologiques et un métabolisme parfois intense. Compte tenu de ces difficultés, la capacité d’identifier et de quantifier ces molécules présente de nombreux écueils sur les plans pré-analytique, analytique et post-analytique. L’objectif de ma thèse était d’appréhender ces difficultés et d’étudier les implications des endocannabinoïdes, et des cannabinoïdes en général, dans les domaines de la toxicologie biologique et médico-légale à travers le développement d’outils analytiques permettant leurs mises en évidence dans les différentes matrices biologiques.A cet effet, trois méthodes analytiques de quantification d’endocannabinoïdes et de substances endocannabinoïdes-like dans trois matrices biologiques différentes (plasma, cheveux et spot de sang séché - DBS), ainsi qu’un outil d’exploration de métabolisme in silico des cannabinoïdes de synthèse, ont été développées. Ces outils ont été mis en oeuvre dans 3 projets de recherche et ont permis (i) d’étudier la relation entre cannabinoïdes sériques et insulinorésistance chez des personnes coinfectées VIH-VHC et d’explorer les effets (de la guérison VHC et de la prise de cannabinoïdes) sur les endocannabinoïdes, (ii) d’étudier l’évolution des endocannabinoïdes dans le sang en période post-mortem, et (iii) d’étudier le métabolisme de 13 « nouveaux » cannabinoïdes de synthèse, pour certains, non décrit précédemment dans la littérature, circulant en 2023 sur l’île de Mayotte, France.Au total, ce travail réalisé au cours de ces trois années de thèse m’a permis d’élaborer des outils analytiques de détection et quantification d’endocannabinoïdes et de cannabinoïdes exogènes dans différentes matrices (et avec des méthodes alternatives de prélèvement sanguin) ; outils complétés de procédures in silico de prédiction à la fois du métabolisme et des paramètres analytiques de biomarqueurs (métabolites) d’exposition qui pourront être appliquées à un périmètre élargi en toxicologie biologique et médicolégale.
- Open Access
- 19 April 2024
- Published by Elsevier in Forensic Science International
- Vol. 359, 112030
Synthetic cathinones in drug-facilitated sexual assault: A case report involving the novel generation substituted cathinone N-ethylpentedrone and a review of the literature
- 19 April 2024
- Published by Elsevier in Forensic Science International
- Vol. 359, 112030
Open AccessSynthetic cathinones in drug-facilitated sexual assault: A case report involving the novel generation substituted cathinone N-ethylpentedrone and a review of the literature
- 2 November 2023
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 61 (11) , 1010-1011
The potential of keratinized matrices for the retrospective exploration of repeated ayahuasca use by patients
- 2 November 2023
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 61 (11) , 1010-1011
The potential of keratinized matrices for the retrospective exploration of repeated ayahuasca use by patients
- Open Access
- 31 May 2022
- Published by Oxford University Press (OUP) in Toxicology Research
- Vol. 11 (3) , 529-536
Aldicarb-related suicide attempt cases in North of France (2012–2021)
Aldicarb, a carbamate pesticide banned in France since 2008, represents a persistent risk of human poisoning. There is no up-to-date picture of aldicarb intentional poisonings associated to detailed diagnosis and clinical management of cases to evaluate the effect of its ban on intoxication risk reduction, including suicide. This retrospective epidemiological study describes cases of suicidal intoxication from the Hauts-de-France region between 2012 and 2021 and illustrates this situation through one analytically documented case. 60 cases were collected, mostly presenting a pathognomonic symptomatology. Thirty-five victims presented a muscarinic syndrome (58.3%), 14 a nicotinic syndrome (23.3%), and 37 a central nervous system impairment (61.7%). Hospitalization was necessary for 44 cases (73.3%), with 2 fatal evolutions. Diagnosis was based on the blood cholinesterase activities. Among the 25 cases with toxicology results, 45.8% presented a moderate decrease of acetylcholinesterase activity, whereas 87.5% presented a strong decrease of butyrylcholinesterase activity. Blood or urine detection of aldicarb and its metabolites may be considered in therapeutic management, although their quantification is unlikely to change the emergency medical care. Our study updates epidemiology of aldicarb poisoning at a regional level, highlighting a persisting health threatening situation with banned pesticides. More than 65% of national cases occurred in this agricultural area, aldicarb remaining available from storage of previously purchased products. Robust evidence is presented that acute poisoning is an ongoing major global public health challenge. There is a need for continued international efforts in risk reduction, knowledge, and information strategies.
- 31 May 2022
- Published by Oxford University Press (OUP) in Toxicology Research
- Vol. 11 (3) , 529-536
Open AccessAldicarb-related suicide attempt cases in North of France (2012–2021)
Aldicarb, a carbamate pesticide banned in France since 2008, represents a persistent risk of human poisoning. There is no up-to-date picture of aldicarb intentional poisonings associated to detailed diagnosis and clinical management of cases to evaluate the effect of its ban on intoxication risk reduction, including suicide. This retrospective epidemiological study describes cases of suicidal intoxication from the Hauts-de-France region between 2012 and 2021 and illustrates this situation through one analytically documented case. 60 cases were collected, mostly presenting a pathognomonic symptomatology. Thirty-five victims presented a muscarinic syndrome (58.3%), 14 a nicotinic syndrome (23.3%), and 37 a central nervous system impairment (61.7%). Hospitalization was necessary for 44 cases (73.3%), with 2 fatal evolutions. Diagnosis was based on the blood cholinesterase activities. Among the 25 cases with toxicology results, 45.8% presented a moderate decrease of acetylcholinesterase activity, whereas 87.5% presented a strong decrease of butyrylcholinesterase activity. Blood or urine detection of aldicarb and its metabolites may be considered in therapeutic management, although their quantification is unlikely to change the emergency medical care. Our study updates epidemiology of aldicarb poisoning at a regional level, highlighting a persisting health threatening situation with banned pesticides. More than 65% of national cases occurred in this agricultural area, aldicarb remaining available from storage of previously purchased products. Robust evidence is presented that acute poisoning is an ongoing major global public health challenge. There is a need for continued international efforts in risk reduction, knowledge, and information strategies.
- 1 April 2022
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 28 (15) , 1245-1249
Trends in the Pharmaceutical Design of New Psychoactive Substances Detected in Oral Fluid OF Drivers Around a Music Festival in South-West France: Comparison 2019/2017
Objective: new psychoactive substance use (NPS) is a reality in France, including among drivers. This work aims (i) to report pharmaceutical design of NPS detected in oral fluid (OF) from drivers initially screened for drugs around a music festival in 2019, and (ii) to compare obtained results with those of a previous similar study carried out in 2017 in the same situation (and the same music festival) and according to the same methodology. Methods: OF specimens were recovered from the used devices of the salivary immunochemical tests used by the police during the controls carried out at the entering and leaving the festival. These OF were analyzed using a liquid chromatography coupled with tandem mass spectrometry and high-resolution mass spectrometry methods using mass spectra libraries of approximately 1700 substances including (in 2020) more than 650 NPS and metabolites. Results: NPS were detected in 14 out of the 265 collected OF specimens. Ten NPS were identified (number of identification): APINACA (1), AB-Chminaca (1), 5F-AMB (1), 5F-PB-22 (5), 2C-D (1), methoxetamine (2), ketamine (1), x-CMC (1), 4-MEC (2), ethylone (2). The prevalence of NPS detection in OF (5.2%) is in the same order than the observed one in 2017 (6.8%) but these results are marked by the majority and increasing proportion of synthetic cannabinoids (47% of identified NPS in 2019 vs 25% in 2017), an increase also in the proportion of cathinone derivatives (29% in 2019 vs 6 % in 2017), and a decrease in cyclohexanones (17% in 2019 vs 43% in 2017). Conclusion: these pharmaceutical design trends (2019 vs 2017) observed in a population of drivers around a music festival seem to reflect those that can be seen in more general populations in France, with probably a rise in the consumption of synthetic cannabinoids.
- 1 April 2022
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 28 (15) , 1245-1249
Trends in the Pharmaceutical Design of New Psychoactive Substances Detected in Oral Fluid OF Drivers Around a Music Festival in South-West France: Comparison 2019/2017
Objective: new psychoactive substance use (NPS) is a reality in France, including among drivers. This work aims (i) to report pharmaceutical design of NPS detected in oral fluid (OF) from drivers initially screened for drugs around a music festival in 2019, and (ii) to compare obtained results with those of a previous similar study carried out in 2017 in the same situation (and the same music festival) and according to the same methodology. Methods: OF specimens were recovered from the used devices of the salivary immunochemical tests used by the police during the controls carried out at the entering and leaving the festival. These OF were analyzed using a liquid chromatography coupled with tandem mass spectrometry and high-resolution mass spectrometry methods using mass spectra libraries of approximately 1700 substances including (in 2020) more than 650 NPS and metabolites. Results: NPS were detected in 14 out of the 265 collected OF specimens. Ten NPS were identified (number of identification): APINACA (1), AB-Chminaca (1), 5F-AMB (1), 5F-PB-22 (5), 2C-D (1), methoxetamine (2), ketamine (1), x-CMC (1), 4-MEC (2), ethylone (2). The prevalence of NPS detection in OF (5.2%) is in the same order than the observed one in 2017 (6.8%) but these results are marked by the majority and increasing proportion of synthetic cannabinoids (47% of identified NPS in 2019 vs 25% in 2017), an increase also in the proportion of cathinone derivatives (29% in 2019 vs 6 % in 2017), and a decrease in cyclohexanones (17% in 2019 vs 43% in 2017). Conclusion: these pharmaceutical design trends (2019 vs 2017) observed in a population of drivers around a music festival seem to reflect those that can be seen in more general populations in France, with probably a rise in the consumption of synthetic cannabinoids.
- 13 September 2021
- Published by Wiley in Drug Testing and Analysis
- Vol. 14 (1) , 144-153
Metabolite elucidation of 2‐fluoro‐deschloroketamine (2F‐DCK) using molecular networking across three complementary in vitro and in vivo models
This work first aims to investigate metabolites of 2‐fluoro‐deschloroketamine (2F‐DCK), a new arylcyclohexylamine derivatives (a group of dissociative ketamine‐based substances) using two in vitro experimental approaches, and to compare obtained results by means of molecular networking. Metabolites of 2F‐DCK were investigated using both human liver microsomes (HLMs) and hepatic (HepaRG) cell line incubates using molecular networking approach: 2F‐DCK pure substance was incubated with HLMs for up to 1 h at two concentrations (100 and 500 μM) and with HepaRG cells for two time periods (8 and 24 h) at one concentration (20 μM). In vitro obtained results were subsequently applied to a 2F‐DCK‐related fatality case. In vitro‐produced metabolites were investigated using high‐resolution accurate mass spectrometry using Orbitrap mass analyzer technology. Thirteen metabolites were in vitro produced and several metabolic pathways can be postulated. Seven additional metabolites were found in post‐mortem samples (bile and urine) of the case, comprising three Phase II metabolites, which appear to be minor in vivo metabolites. HLMs and HepaRG cell models appear to be complementary and obtained data allowed the identification of several specific 2F‐DCK metabolites in biological samples. In practical terms, observed metabolic ratios suggested that nor‐2F‐DCK (208.1137 m/z) and a hydrogenated metabolite (224.1443 m/z) could be proposed as reliable metabolites to be recorded in HRMS libraries in order to improve detection of 2F‐DCK use.
- 13 September 2021
- Published by Wiley in Drug Testing and Analysis
- Vol. 14 (1) , 144-153
Metabolite elucidation of 2‐fluoro‐deschloroketamine (2F‐DCK) using molecular networking across three complementary in vitro and in vivo models
This work first aims to investigate metabolites of 2‐fluoro‐deschloroketamine (2F‐DCK), a new arylcyclohexylamine derivatives (a group of dissociative ketamine‐based substances) using two in vitro experimental approaches, and to compare obtained results by means of molecular networking. Metabolites of 2F‐DCK were investigated using both human liver microsomes (HLMs) and hepatic (HepaRG) cell line incubates using molecular networking approach: 2F‐DCK pure substance was incubated with HLMs for up to 1 h at two concentrations (100 and 500 μM) and with HepaRG cells for two time periods (8 and 24 h) at one concentration (20 μM). In vitro obtained results were subsequently applied to a 2F‐DCK‐related fatality case. In vitro‐produced metabolites were investigated using high‐resolution accurate mass spectrometry using Orbitrap mass analyzer technology. Thirteen metabolites were in vitro produced and several metabolic pathways can be postulated. Seven additional metabolites were found in post‐mortem samples (bile and urine) of the case, comprising three Phase II metabolites, which appear to be minor in vivo metabolites. HLMs and HepaRG cell models appear to be complementary and obtained data allowed the identification of several specific 2F‐DCK metabolites in biological samples. In practical terms, observed metabolic ratios suggested that nor‐2F‐DCK (208.1137 m/z) and a hydrogenated metabolite (224.1443 m/z) could be proposed as reliable metabolites to be recorded in HRMS libraries in order to improve detection of 2F‐DCK use.